New Haven-based online pharmacy Valisure’s CEO David Light spoke at the June 18 session of the WHIPgroup Tech Entrepreneur Meetup at our Stamford offices.
David and Valisure are in the news this week. They are the source for the troubling news that popular and effective acid-blocking drug Zantac and its generic form Radnitidine contain the known carcinogen NDMA.
In his talk at WHIPgroup, David led a fascinating discussion on the reasons impurities can get into the global drug supply and the tests, procedures and processes that Valisure uses to ensure their customers receive medications that are efficacious, at the right dosage, and free of harmful impurities.
If you would like to learn more about how Valisure found the NDMA in Zantac and other forms of Radnitidine, please click here.
If you would like to meet other leaders on the leading edge of technology, business and science, please join the WHIPgroup Meetup by clicking here. Our next session will be on October 15 and will explore the significant aquaculture business opportunity around Kelp farming in Long Island Sound.
By Alan Harrison The USPTO issued a Guidance Update, effective July 17, 2024, to address the evolving landscape of patent eligibility, particularly in relation to artificial intelligence (AI). It seeks to clarify and update the [Read More…]
By Meghan E. McDermott Today, branding is everything – it is arguably one of the most important assets a company can have. So, whether you are starting a new brand or re-branding, any type of [Read More…]
Copyright law includes an interesting clause at 17 U.S.C. § 203: (3) Termination of the grant may be effected at any time during a period of five years beginning at the end of thirty-five years [Read More…]